Industry Voice: Biotech stocks perform well

clock
Industry Voice: Biotech stocks perform well

Equity markets performed well in the first quarter driven by an expectation of lower corporate tax rates in the US and the potential repatriation of offshore cash and investments in infrastructure.

The S&P 500 gained 6.1%, the Dow Jones gained 5.2% and the Nasdaq Composite Index gained 10.1 (all values in USD).

In the healthcare space Swiss investment company BB Biotech earned a bottom-line profit of CHF 375 mn and its share price advanced 7.7% in CHF and 7.1% in EUR through to 31st March. Profits were generated from core positions in Incyte, Celgene and Actelion - creating a cash increase in other positions such as Novo Nordisk, Ionis and in several of its mid-sized investments. Continuing a strategy of investing in promising smaller and mid-cap companies, the group also added Five Prime Therapeutics to its portfolio in Q1. 

In the near term BB Biotech expects the healthcare reform debate in the US to simmer against a backdrop of late stage clinical trial read-outs and an increase in the number of product approvals. Further merger and acquisition activity is expected to drive performance in the sector and in particular Johnson & Johnson's acquisition of Actelion will likely deliver significant cash for BB Biotech in the second quarter.

For the remainder of 2017, the group will consider selective increases in undervalued portfolio positions and continue to add promising new smaller and mid-cap positions to its investment portfolio.

For more information, please contact Claude Mikkelsen

[email protected], +44 203 770 67 85, www.bbbiotech.com

Disclaimer

All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

More on Industry Voice

Industry Voice: Supporting change through change makers

Industry Voice: Supporting change through change makers

Why KPMG is proud to sponsor the Sustainable and ESG Investment Woman of the Year Award

KPMG
clock 17 November 2021 • 3 min read
Partner Insight: Seven urgent reasons to explore impact-aligned debt investing

Partner Insight: Seven urgent reasons to explore impact-aligned debt investing

BlueBay’s My-Linh Ngo, and Tom Moulds explain how they defined their new ‘impact aligned’ debt strategy around global challenges and the ‘sunrise’ industries tackling them

BlueBay
clock 12 November 2021 • 6 min read
Industry Voice: Cows, methane and the climate threat

Industry Voice: Cows, methane and the climate threat

Methane can be a more threatening pollutant than carbon dioxide when it comes to the greenhouse gases behind global warming. Our portfolio managers and analysts discuss a number of pioneering new methods to avoid or reduce emissions from livestock, and...

Gita Bal, Global Head of Research, Fixed Income and Velislava Dimitrova, Portfolio Manager, Fidelity Global Sustainable Climate Solutions Fund, Fidelity International
clock 20 September 2021 • 6 min read